{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:07:27Z","timestamp":1791313647119,"version":"4.3.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol-Myers Squibb K.K."},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12969-019-0319-4","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T10:14:10Z","timestamp":1556619250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study"],"prefix":"10.1186","volume":"17","author":[{"given":"Ryoki","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Umebayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuji","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Nakagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Kizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Imagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihito","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumpei","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"issue":"9563","key":"319_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet."},{"issue":"5","key":"319_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/s10165-007-0625-4","volume":"17","author":"S Yokota","year":"2007","unstructured":"Yokota S, Mori M, Imagawa T, Takei S, Murata T, Tomiita M, et al. Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007). Mod Rheumatol. 2007;17(5):353\u201363.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"319_CR3","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"key":"319_CR4","first-page":"217","volume-title":"Textbook of pediatric rheumatology","author":"AM Rosenberg","year":"2015","unstructured":"Rosenberg AM, Oen KG. Polyarticular juvenile idiopathic arthritis. In: Petty RE, Laxer RM, CB L, Wedderburn LR, editors. Textbook of pediatric rheumatology. 7th ed. Philadelphia: Elsevier Health Sciences; 2015. p. 217.","edition":"7"},{"issue":"4","key":"319_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465\u201382.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"5","key":"319_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/BOR.0000000000000206","volume":"27","author":"K Webb","year":"2015","unstructured":"Webb K, Wedderburn LR. Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol. 2015;27(5):505\u201310.","journal-title":"Curr Opin Rheumatol"},{"key":"319_CR7","unstructured":"Orencia Prescribing Information [in Japanese]2017 2\/2\/2018. Available from: \n                    https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuSearch\/\n                    \n                  ."},{"key":"319_CR8","unstructured":"Humira Prescribing Information 2017 2\/2\/2018. Available from: \n                    http:\/\/www.pmda.go.jp\/files\/000224547.pdf\n                    \n                  ."},{"key":"319_CR9","unstructured":"Actemra Prescribing Information 2017 2\/2\/2018. Available from: \n                    http:\/\/www.pmda.go.jp\/files\/000224730.pdf\n                    \n                  ."},{"key":"319_CR10","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"319_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"HI Brunner","year":"2018","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77(1):21\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"319_CR12","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1002\/art.39234","volume":"67","author":"D Lovell","year":"2015","unstructured":"Lovell D, Ruperto N, Mouy R, Paz E, Rubio-P\u00e9rez N, Silva CA, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015;67(10):2759\u201370.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"319_CR13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"319_CR14","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"319_CR15","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/art.27431","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1792\u2013802.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"319_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/art.20861","volume":"52","author":"E Silverman","year":"2005","unstructured":"Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52(2):554\u201362.","journal-title":"Arthritis Rheum"},{"issue":"16","key":"319_CR17","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMoa041810","volume":"352","author":"E Silverman","year":"2005","unstructured":"Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352(16):1655\u201366.","journal-title":"N Engl J Med"},{"issue":"4","key":"319_CR18","doi-asserted-by":"publisher","first-page":"R112","DOI":"10.1186\/ar2001","volume":"8","author":"B Vander Cruyssen","year":"2006","unstructured":"Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther. 2006;8(4):R112.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"319_CR19","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/art.10294","volume":"46","author":"LW Moreland","year":"2002","unstructured":"Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46(6):1470\u20139.","journal-title":"Arthritis Rheum"},{"key":"319_CR20","unstructured":"Orencia Prescribing Information2017 February 2, 2018. Available from: \n                    http:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf\n                    \n                  ."},{"issue":"4","key":"319_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1586\/1744666X.2016.1133295","volume":"12","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Sulli A, Paolino S, Pizzorni C. CTLA-4 blockade in the treatment of rheumatoid arthritis: an update. Expert Rev Clin Immunol. 2016;12(4):417\u201325.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"319_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67(4):547\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"319_CR23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/art.23397","volume":"58","author":"JM Kremer","year":"2008","unstructured":"Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008;58(4):953\u201363.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"319_CR24","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3899\/jrheum.080813","volume":"36","author":"R Westhovens","year":"2009","unstructured":"Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009;36(4):736\u201342.","journal-title":"J Rheumatol"},{"issue":"Suppl 10","key":"319_CR25","first-page":"Abstract 2272","volume":"69","author":"D Lovell","year":"2017","unstructured":"Lovell D, Ruperto N, Tzaribachev N, Zeft A, Cimaz R, Stanevica V, et al. Long-term effectiveness and safety of abatacept in juvenile idiopathic arthritis: interim results from the abatacept in JIA registry [abstract]. Arthritis Rheumatol. 2017;69(Suppl 10):Abstract 2272.","journal-title":"Arthritis Rheumatol."},{"issue":"9636","key":"319_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383\u201391.","journal-title":"Lancet."},{"key":"319_CR27","unstructured":"Bristol-Myers Squibb Canada. Orencia (abatacept) product monograph 2017 [Available from: \n                    http:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/ORENCIA_EN_PM.pdf\n                    \n                  ."},{"key":"319_CR28","unstructured":"Orencia 250 mg powder for concentrate for solution for infusion 2017 [Available from: \n                    http:\/\/www.medicines.org.uk\/emc\/medicine\/19714\/SPC\/\n                    \n                  ."},{"key":"319_CR29","unstructured":"Bristol-Myers Squibb K.K., Ono Pharmaceutical Co. L. Orencia\u00ae for Intravenous Infusion 250 mg, Selective T-cell Co-stimulation Modulator: Approval for Additional Indication of Active Polyarticular Juvenile Idiopathic Arthritis for Partial Change in Approved items of Manufacturing and Marketing Approval in Japan 2018 [Available from: \n                    https:\/\/www.ono.co.jp\/eng\/news\/pdf\/sm_cn180223.pdf\n                    \n                  ."},{"issue":"7","key":"319_CR30","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"319_CR31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/acr.20497","volume":"63","author":"CA Wallace","year":"2011","unstructured":"Wallace CA, Giannini EH, B H, L I, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929\u201336.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4 Suppl 23","key":"319_CR32","first-page":"S1","volume":"19","author":"N Ruperto","year":"2001","unstructured":"Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the childhood health assessment questionnaire (CHAQ) and the child health questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol. 2001;19(4 Suppl 23):S1\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"319_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658\u201366.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"319_CR34","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/art.34373","volume":"64","author":"A Consolaro","year":"2012","unstructured":"Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64(7):2366\u201374.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"319_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/acr.22215","volume":"66","author":"AF Mourao","year":"2014","unstructured":"Mourao AF, Santos MJ, Melo-Gomes J, Martins FM, Costa JA, Ramos F, et al. Using the juvenile arthritis disease activity score based on erythrocyte sedimentation rate or C-reactive protein level: results from the Portuguese register. Arthritis Care Res (Hoboken). 2014;66(4):585\u201391.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"319_CR36","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1136\/annrheumdis-2011-200237","volume":"71","author":"EB Nordal","year":"2012","unstructured":"Nordal EB, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis. 2012;71(7):1122\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"319_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00228-010-0937-8","volume":"67","author":"N Ruperto","year":"2011","unstructured":"Ruperto N, Pistorio A, Ravelli A, Hasija R, Guseinova D, Filocamo G, et al. Criteria to define response to therapy in paediatric rheumatic diseases. Eur J Clin Pharmacol. 2011;67(Suppl 1):125\u201331.","journal-title":"Eur J Clin Pharmacol"},{"key":"319_CR38","unstructured":"European Medicines Agency. Assessment Report: Orenica; Procedure No. EMEA\/H\/C\/000701\/II\/01052017 2\/2\/2018. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000701\/WC500233148.pdf\n                    \n                  ."},{"issue":"12","key":"319_CR39","first-page":"2365","volume":"34","author":"HG Haggerty","year":"2007","unstructured":"Haggerty HG, Abbott MA, Reilly TP, DeVona DA, Gleason CR, Tay L, et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol. 2007;34(12):2365\u201373.","journal-title":"J Rheumatol"},{"issue":"1","key":"319_CR40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/s10165-011-0481-0","volume":"22","author":"T Imagawa","year":"2012","unstructured":"Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012;22(1):109\u201315.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"319_CR41","first-page":"865","volume":"2","author":"JB Kuemmerle-Deschner","year":"2008","unstructured":"Kuemmerle-Deschner JB, Benseler S. Abatacept in difficult-to-treat juvenile idiopathic arthritis. Biologics. 2008;2(4):865\u201374.","journal-title":"Biologics."},{"issue":"6","key":"319_CR42","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s11136-004-7710-3","volume":"14","author":"MG Sawyer","year":"2005","unstructured":"Sawyer MG, Carbone JA, Whitham JN, Roberton DM, Taplin JE, Varni JW, et al. The relationship between health-related quality of life, pain, and coping strategies in juvenile arthritis--a one year prospective study. Qual Life Res. 2005;14(6):1585\u201398.","journal-title":"Qual Life Res"},{"issue":"Suppl. 85","key":"319_CR43","first-page":"S126","volume":"32","author":"A Consolaro","year":"2014","unstructured":"Consolaro A, Schiappapietra B, Dalpra` S, Calandra S, Martini A, Ravelli A. Optimisation of disease assessments in juvenile idiopathic arthritis. Clinical Exp Rheumatol. 2014;32(Suppl. 85):S126\u2013S30.","journal-title":"Clinical Exp Rheumatol"},{"key":"319_CR44","unstructured":"Li X, Passarell JA, Lin K, Roy A, Murthy B, Girgis IG. Population pharmacokinetics and exposure-response analyses for abatacept in juvenile idiopathic arthritis. American Conference on Pharmacometrics (ACoP8), Fort Lauderdale, FL, USA, 15\u201318 October, abstract W-069; 20172017."},{"issue":"6","key":"319_CR45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3109\/14397595.2014.881954","volume":"24","author":"M Iwahashi","year":"2014","unstructured":"Iwahashi M, Inoue H, Matsubara T, Tanaka T, Amano K, Kanamono T, et al. Efficacy, safety, pharmacokinetics, and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a phase II\/III, randomized study. Mod Rheumatol. 2014;24(6):885\u201391.","journal-title":"Mod Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0319-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-019-0319-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0319-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T06:03:45Z","timestamp":1589868225000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-019-0319-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1186\/s12969-019-0319-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735732234.793582480","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]},"assertion":[{"value":"17 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guidelines for Good Clinical Practice, and local regulations. An institutional review board or independent ethics committee at each site approved the protocol, consent form, and any other written information provided to patients or their legal representatives.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.M. received research grants from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma, UCB Japan Co., Ltd., CSL Behring, Towa Pharmaceutical Co., Ltd., AbbVie Japan Co., Ltd., Japan Blood Products Organization, Ayumi Pharmaceutical Co. and Nippon Kayaku Co., Ltd.; speaker fees from MSD K.K; and consulting fees from Daiichi Sankyo Co., Ltd. and Taisho Pharmaceutical Co., Ltd. N.A. and Y.T. are employees of Bristol-Myers Squibb K.K. All other authors declare no conflicts of interest associated with this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"17"}}